Theodoros Karkantzos
About Theodoros Karkantzos
Theodoros C. Karkantzos is a nominee for director at Cosmos Health (COSM) as of August 2025, age 38, with 15+ years of investment and business development experience spanning finance, strategy, private equity, and asset management . He is Co‑Founder of Blue Dot Digital Agency, and a private investor across real estate, healthcare, equities, and hospitality . He holds an MPhil in Real Estate Finance (University of Cambridge, Distinction; Alister Ross‑Goobey Award; RICS Award) and a BSc in Management (University of Warwick, First Class Honours) .
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Blue Dot Digital Agency | Co‑Founder | c. 15 years of investment/business development experience | Corporate communications; finance/strategy expertise |
| Private investing (real estate, healthcare, equities, hospitality) | Investor | c. 15 years | Asset allocation and business development across sectors |
External Roles
| Organization | Role | Tenure | Notes |
|---|---|---|---|
| None disclosed | — | — | No public company directorships disclosed in nominee bio |
Board Governance
- Status: Nominee for director; independence of the nominee is not explicitly stated. The Board lists independent directors as John Hoidas, Dr. Anastasios Aslidis, and Demetrios G. Demetriades . The company states all Board committee members are independent and asserts all Board members are independent, though the CEO serves on the Board .
- Lead Independent Director: Company does not have a lead independent director .
- Committee landscape (latest proxy): Audit Committee—Hoidas, Aslidis, Demetriades (Aslidis is the financial expert) ; Compensation Committee—Hoidas, Aslidis ; Nominating & Corporate Governance—Siokas, Demetriades . Karkantzos is not listed on any committee (nominee stage) .
- Attendance: Board met 2 times in 2024 (9 unanimous consents); directors attended 100% of meetings . In 2023, Board met 15 times; all directors attended at least 75%; Audit Committee held 3 meetings with 100% attendance by members .
Board activity and attendance (quantitative):
| Metric | 2023 | 2024 |
|---|---|---|
| Board meetings held | 15 | 2 |
| Board unanimous consents | 13 | 9 |
| Director attendance rate | ≥75% | 100% |
| Audit Committee meetings | 3 | 1 |
| Audit Committee attendance | 100% | 100% |
Fixed Compensation
- No director compensation disclosed for Karkantzos (he is a nominee and not included in director compensation tables) . Existing director cash retainers and committee fees are shown for other directors in 2024 and 2023, but none apply specifically to him .
Performance Compensation
- No equity or performance awards disclosed for Karkantzos (not included in director stock award tables; nominee stage) . Company equity plans (2024 and proposed 2025) permit RSUs/PSUs and performance goals generally, but no director‑specific performance metrics for Karkantzos are disclosed .
Other Directorships & Interlocks
- None disclosed; his biography lists Blue Dot Digital Agency and private investing activities without other public boards or known interlocks .
Expertise & Qualifications
- Education: MPhil Real Estate Finance, University of Cambridge (Distinction; Alister Ross‑Goobey Award; RICS Award); BSc Management, University of Warwick (First Class Honours) .
- Domain skills: Finance, strategy, private equity, asset management; corporate communications/digital marketing (Blue Dot Digital) .
- Years of experience: 15+ years investment/business development .
Equity Ownership
- Not listed among named directors/officers in the beneficial ownership table as of August 1, 2025; table covers Siokas, Bhutawala, Bardakis, Terzis, Demetriades, Hoidas, Aslidis, and group totals, but does not include Karkantzos (nominee status) .
Governance Assessment
- Independence & roles: As a nominee, committee assignments and formal independence designation for Karkantzos are not disclosed; Board committees are chaired by and composed of independent directors, with an audit financial expert in place . Lack of a lead independent director diminishes independent board leadership signaling .
- Attendance & engagement: Latest disclosed Board/committee attendance is strong (100% in 2024; high in 2023), a positive governance signal; applicability to Karkantzos will depend on post‑election participation .
- Compensation alignment: No director pay disclosed for Karkantzos yet; context shows a mix of cash retainers and equity grants for other directors, without clear, disclosed director performance metrics .
- Policies & red flags:
- Company lacks anti‑hedging and anti‑pledging policies, which weakens alignment safeguards for insiders and directors (RED FLAG) .
- Significant related‑party transactions persist with Doc Pharma (run by the CEO’s spouse), including inventory purchases, licenses, loans, and prepayments—heightened conflict‑of‑interest environment requiring strong independent oversight (RED FLAG) .
- Capital actions signaling: Repeat proposals to authorize reverse stock splits (discretionary, to maintain Nasdaq listing) and large increases in authorized shares can be dilutive and indicate financing reliance; they heighten the need for independent directors to safeguard minority shareholders .
- Section 16 compliance: Prior late filings were reported for several insiders (not including Karkantzos), indicating past control weaknesses but not tied to him .
Implications: Given the company’s related‑party exposure and absence of anti‑hedging/pledging policies, an engaged, truly independent director with finance and strategy expertise can bolster board effectiveness. Post‑election, monitor whether Karkantzos joins key committees (audit/compensation/nominating), his meeting attendance, stock ownership (and any pledging/hedging), and any service relationships between Blue Dot Digital and COSM that could introduce conflicts (none disclosed to date) .
RED FLAGS
- No anti‑hedging/anti‑pledging policies (alignment risk) .
- Extensive related‑party transactions with entities controlled by the CEO/spouse (conflict risk) .
- Discretionary reverse stock split authority and major authorized share increases (potential dilution/financing risk) .
Notes
- Karkantzos is a nominee (not yet an elected director in the 2025 proxy), so compensation, ownership, and committee assignments specific to him are not disclosed; reassess after the annual meeting .